Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02336594 · ClinicalTrials.gov registry record · Phase 1
RDEA3170 Bioavailability Study
A Phase 1 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02336594 is a Phase 1 study that has completed, run by Ardea Biosciences. The registered enrollment target is 15 participants.
The verdict
NCT02336594, a Phase 1 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a Phase 1, randomized, open-label, 4-way crossover pharmacokinetic (PK) and pharmacodynamic (PD) study in healthy adult male subjects designed to assess the relative bioavailability of RDEA3170 2.5 mg tablets administered as a 10 mg dose (2.5 mg × 4 tablets) and of a single RDEA3170 10 mg tablet. This study will also assess the effect of a low-fat and high-fat meal on the PK and PD of RDEA3170 10 mg tablets.
Interventions
- DRUG RDEA3170 10 mg
- DRUG RDEA3170 2.5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02336594
The ClinicalTrials.gov registry entry for NCT02336594 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RDEA3170 10 mg is the first listed.
NCT02336594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02336594 about?
NCT02336594 is a clinical study titled "RDEA3170 Bioavailability Study". This is a Phase 1, randomized, open-label, 4-way crossover pharmacokinetic (PK) and pharmacodynamic (PD) study in healthy adult male subjects designed to assess the relative bioavailability of RDEA3170 2.5 mg tablets administered as a 10 mg dose (2.5 mg × 4 tablets) and of a single RDEA3170 10 mg ta...
What is the current status of trial NCT02336594?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-11. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02336594?
The interventions under investigation include: RDEA3170 10 mg (DRUG), RDEA3170 2.5 mg (DRUG).
Who is sponsoring clinical trial NCT02336594?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.